Positron emission tomography after first cycle of chemotherapy predicts outcome at one year in aggressive lymphoma and hodgkin's disease Academic Article uri icon


MeSH Major

  • Biomedical Research
  • Genetic Association Studies
  • Lymphoma
  • Translational Medical Research


  • Early identification of chemotherapy refractory patients with lymphoma may indicate a need for alternative treatment strategies to optimize the possibility for cure. Metabolic imaging with positron emission tomography using F-18 fluorodeoxyglucose (FDG-PET) offers advantages of functional tissue characterization that can be used to assess response to therapy. Our purpose was to evaluate the predictive value of FDG-PET early during chemotherapy for subsequent failure-free survival in patients with aggressive nonHodgkin's (NHL) and Hodgkin's lymphoma (HD). Materials and Methods: FDG-PET was performed prior to and after one cycle of chemotherapy in 27 patients ( 17 NHL and 10 HD). All patients had a follow-up period of at least 12 months. The 1-year failure-free survival was compared between patients with positive and negative FDG-PET obtained after first cycle of chemotherapy. ANOVA test was used for statistical analysis. Results: The results are presented below (Prog/Recur: progression or recurrence, CR:complete remission). The differences in failure-free survival between patients with positive versus negative FDGPET findings were statistically significant (p=0.0004). The positive and negative predictive values for FDG-PET were 83.3% and 80%, respectively. Conclusion: FDG-PET findings after one-cycle of chemotherapy are predictive of one-year outcome in patients with aggressive NHL and HD. Therefore early FDG-PET imaging during chemotherapy may be a good indicator of patients who could potentially benefit from a change to a more intensive treatment program. FDG PET + FDG PET - Prog/Recur 10 3 CR 2 12.

publication date

  • December 2000



  • Academic Article

Additional Document Info

start page

  • 225b


  • 96


  • 11 PART II